• Home
  • Agent Gallery
  • Templates
  • Chat with PDF
  • Literature Review
  • AI Writer
  • Find Topics
  • Paraphraser
  • Citation Generator
  • Extract Data
  • AI Detector
  • AI Humanizer
Scispace (Formerly Typeset)
  1. Home
  2. Journals
  3. Neuromuscular Disorders
  4. 2020
  1. Home
  2. Journals
  3. Neuromuscular Disorders
  4. 2020
Showing papers in "Neuromuscular Disorders in 2020"
Journal Article•10.1016/J.NMD.2019.10.005•
239th ENMC International Workshop: Classification of dermatomyositis, Amsterdam, the Netherlands, 14-16 December 2018.

[...]

Andrew L. Mammen1, Yves Allenbach2, Werner Stenzel3, Olivier Benveniste2•
National Institutes of Health1, University of Paris2, Charité3
01 Jan 2020-Neuromuscular Disorders

214 citations

Journal Article•10.1016/J.NMD.2019.11.002•
244th ENMC international workshop: Newborn screening in spinal muscular atrophy May 10-12, 2019, Hoofdorp, The Netherlands.

[...]

Tamara Dangouloff1, Arthur H.M. Burghes2, Eduardo F. Tizzano, Laurent Servais3•
University of Liège1, Ohio State University2, University of Oxford3
01 Jan 2020-Neuromuscular Disorders
TL;DR: In this article, the authors propose a solution to solve the problem of the problem: REINFORCE/RESUME 7, 2019....,.. ).

64 citations

Journal Article•10.1016/J.NMD.2020.06.010•
Fatigue in patients with myasthenia gravis. A systematic review of the literature.

[...]

Annabel M. Ruiter1, Jan J.G.M. Verschuuren1, Martijn R. Tannemaat1•
Leiden University Medical Center1
01 Jul 2020-Neuromuscular Disorders
TL;DR: Fatigue is a highly prevalent symptom of MG with a severe negative impact on quality of life and Physicians treating patients with MG should be aware of this symptom, as it may be treatable with physical or psychological training programs.

63 citations

Journal Article•10.1016/J.NMD.2020.05.001•
Combining genetics, neuropsychology and neuroimaging to improve understanding of brain involvement in Duchenne muscular dystrophy - a narrative review

[...]

N. Doorenweerd1•
Leiden University Medical Center1
16 May 2020-Neuromuscular Disorders
TL;DR: The latest findings on dystrophin isoform expression in the brain; specific DMD-associated learning and behavioural difficulties; and imaging and spectroscopy findings relating to brain structure, networks, perfusion and metabolism are reviewed.

61 citations

Journal Article•10.1016/J.NMD.2020.11.009•
The 2021 version of the gene table of neuromuscular disorders (nuclear genome).

[...]

Louise Benarroch1, Gisèle Bonne1, François Rivier2, Dalil Hamroun•
University of Paris1, University of Montpellier2
22 Nov 2020-Neuromuscular Disorders
TL;DR: The 2021 version of the gene table of neuromuscular disorders (nuclear genome) Louise Benarroch, Gisèle Bonne, Francois Rivier, Dalil Hamroun.

54 citations

Journal Article•10.1016/J.NMD.2020.05.002•
Randomized phase 2 trial and open-label extension of domagrozumab in Duchenne muscular dystrophy

[...]

Kathryn R. Wagner1, Hoda Abdel-Hamid2, Jean K. Mah3, Craig Campbell4, Michela Guglieri5, Francesco Muntoni6, Yasuhiro Takeshima7, Craig M. McDonald8, Anna Kostera-Pruszczyk9, Peter I. Karachunski10, Russell J. Butterfield11, Eugenio Mercuri12, Eugenio Mercuri13, Chiara Fiorillo, Enrico Bertini, C. Tian14, J. Statland15, Alesia Sadosky16, Vivek S. Purohit16, Sarah P. Sherlock16, Jeffrey P. Palmer16, Michael Binks16, Lawrence Charnas16, Shannon Marraffino16, Brenda L. Wong17 •
Johns Hopkins University1, University of Pittsburgh2, Alberta Children's Hospital3, University of Western Ontario4, Newcastle University5, University College London6, Hyogo College of Medicine7, University of California, Berkeley8, Medical University of Warsaw9, University of Minnesota10, University of Utah11, Agostino Gemelli University Polyclinic12, Catholic University of the Sacred Heart13, University of Cincinnati14, University of Kansas15, Pfizer16, University of Massachusetts Medical School17
01 Jun 2020-Neuromuscular Disorders
TL;DR: Domagrozumab was generally safe and well tolerated in patients with DMD and its open-label extension and Efficacy measures did not support a significant treatment effect.

49 citations

Journal Article•10.1016/J.NMD.2020.02.017•
Chronic pain is common in mitochondrial disease.

[...]

Jelle van den Ameele1, Jelle van den Ameele2, Joshua Fuge2, Robert D S Pitceathly3, Sarah Berry2, Zoe McIntyre2, Michael G. Hanna3, Michael C. Lee2, Patrick F. Chinnery4, Patrick F. Chinnery2 •
Wellcome Trust/Cancer Research UK Gurdon Institute1, University of Cambridge2, UCL Institute of Neurology3, MRC Mitochondrial Biology Unit4
29 Feb 2020-Neuromuscular Disorders
TL;DR: Chronic pain is common in patients with mitochondrial disease and the distribution, intensity and type of pain are genetically determined.

35 citations

Journal Article•10.1016/J.NMD.2020.02.015•
Strength-training effectively alleviates skeletal muscle impairments in myotonic dystrophy type 1

[...]

Marie-Pier Roussel1, Luc J. Hébert2, Élise Duchesne1, Élise Duchesne3•
Université du Québec à Chicoutimi1, Laval University2, Université de Sherbrooke3
28 Feb 2020-Neuromuscular Disorders
TL;DR: Analysis showed that individual abnormalhypertrophy factor at baseline could explain the different changes in muscle size among participants, and could be a key component to identify high and low responders to hypertrophy in DM1.

34 citations

Journal Article•10.1016/J.NMD.2020.07.005•
Age and baseline values predict 12 and 24-month functional changes in type 2 SMA.

[...]

Giorgia Coratti1, Giorgia Coratti2, Maria Carmela Pera1, Maria Carmela Pera2, Simona Lucibello2, Simona Lucibello1, Jacqueline Montes3, Amy Pasternak4, Anna Mayhew5, Allan M. Glanzman6, Sally Dunaway Young7, Marika Pane1, Mariacristina Scoto8, Sonia Messina9, Nathalie Goemans10, Andres Nascimiento Osorio, Marina Pedemonte11, Valeria Sansone12, Enrico Bertini4, Darryl C. De Vivo3, Richard S. Finkel13, Francesco Muntoni8, Francesco Muntoni14, Eugenio Mercuri2, Eugenio Mercuri1 •
Agostino Gemelli University Polyclinic1, Catholic University of the Sacred Heart2, Columbia University3, Boston Children's Hospital4, Newcastle University5, Children's Hospital of Philadelphia6, Stanford University7, UCL Institute of Child Health8, University of Messina9, Katholieke Universiteit Leuven10, Istituto Giannina Gaslini11, University of Milan12, University of Central Florida13, Great Ormond Street Hospital14
25 Jul 2020-Neuromuscular Disorders
TL;DR: The combination of age and HFMSE scores at baseline increased the ability to predict progression in type 2 SMA.

34 citations

Journal Article•10.1016/J.NMD.2020.07.004•
Gain and loss of abilities in type II SMA: A 12-month natural history study.

[...]

Giorgia Coratti1, Simona Lucibello1, Maria Carmela Pera1, Tina Duong2, Robert Muni Lofra3, Matthew Civitello4, Adele D'Amico5, Nathalie Goemans6, Basil T. Darras5, Claudio Bruno7, Valeria A. Sansone8, John W. Day2, Andrés Nascimento Osorio, Francesco Muntoni9, Jaccqueline Montes10, Maria Sframeli11, Richard S. Finkel4, Eugenio Mercuri12, Eugenio Mercuri1 •
Agostino Gemelli University Polyclinic1, Stanford University2, Newcastle University3, University of Central Florida4, Boston Children's Hospital5, Katholieke Universiteit Leuven6, Istituto Giannina Gaslini7, University of Milan8, UCL Institute of Child Health9, Columbia University10, University of Messina11, Catholic University of the Sacred Heart12
13 Jul 2020-Neuromuscular Disorders
TL;DR: The peak of abilities gained occurred before the age of 5 years while the highest number of lost abilities was found in the group 5-13 years, and a correlation between the HFMSE baseline score and the ordinal number of the items was found.

32 citations

Journal Article•10.1016/J.NMD.2019.12.003•
Emerging therapies for autoimmune myasthenia gravis: Towards treatment without corticosteroids.

[...]

Martijn R. Tannemaat1, Jan J.G.M. Verschuuren1•
Leiden University Medical Center1
01 Feb 2020-Neuromuscular Disorders
TL;DR: Future trials should select patients with weakness and fatigability that is completely explained by their myasthenia gravis, use a design that avoids the exclusion of patients with recent changes in medication, and explore the possibilities to completely avoid the use of corticosteroids.
Journal Article•10.1016/J.NMD.2019.11.005•
Mutations in the J domain of DNAJB6 cause dominant distal myopathy.

[...]

Johanna Palmio, Per Harald Jonson1, Michio Inoue, Jaakko Sarparanta1, Rocio Bengoechea2, Marco Savarese1, Anna Vihola1, Manu Jokela3, Masanori Nakagawa4, Satoru Noguchi, Montse Olivé5, Marion Masingue6, Emilia Kerty7, Peter Hackman1, Conrad C. Weihl2, Ichizo Nishino, Bjarne Udd1 •
University of Helsinki1, Washington University in St. Louis2, Turku University Hospital3, Kyoto Prefectural University of Medicine4, Bellvitge University Hospital5, Pierre-and-Marie-Curie University6, Oslo University Hospital7
01 Jan 2020-Neuromuscular Disorders
TL;DR: The identified mutations in the J domain cause dominant distal and proximo-distal Myopathy, confirming that mutations in DNAJB6 should be considered in distal myopathy cases.
Journal Article•10.1016/J.NMD.2020.02.018•
Cognitive impairment appears progressive in the mdx mouse

[...]

Emine Bagdatlioglu1, Paola Porcari2, E. Greally1, Andrew M. Blamire2, Volker Straub1 •
Centre for Life1, Newcastle University2
04 Mar 2020-Neuromuscular Disorders
TL;DR: Longitudinal magnetic resonance imaging identified increased total brain volume in older mdx mice and deficits in hippocampal long-term spatial learning and memory and increased levels of anxiety-related behaviour shown by older m dx mice.
Journal Article•10.1016/J.NMD.2019.11.008•
Paediatric myasthenia gravis: Prognostic factors for drug free remission.

[...]

Domizia Vecchio1, Sithara Ramdas2, Pinki Munot3, Matthew Pitt4, David Beeson1, Ravi Knight1, Pedro M. Rodríguez Cruz1, Angela Vincent1, Sandeep Jayawant2, Catherine DeVile3, Camilla Buckley1, David Hilton-Jones1, Stephanie A. Robb3, Jackie Palace1 •
University of Oxford1, John Radcliffe Hospital2, Great Ormond Street Hospital3, Great Ormond Street Hospital for Children NHS Foundation Trust4
01 Feb 2020-Neuromuscular Disorders
TL;DR: In a multifactorial regression analysis, the antibody status was the only significant predictor for drug free remission, with 60% of patients with antibodies only to clustered AChR achieving this outcome.
Journal Article•10.1016/J.NMD.2020.08.355•
Mortality rates and causes of death in Swedish Myasthenia Gravis patients

[...]

Elisabet Westerberg1, Anna Rostedt Punga1•
Uppsala University1
12 Aug 2020-Neuromuscular Disorders
TL;DR: It was observed that MG itself was stated as the third most common ultimate cause of death in Swedish MG patients, and there was a strikingly higher likelihood of having influenza/pneumonia as a contributing cause ofdeath.
Journal Article•10.1016/J.NMD.2019.10.006•
Nivolumab and Ipilimumab-induced myositis and myocarditis mimicking a myasthenia gravis presentation.

[...]

Rafael Valenti-Azcarate1, Inés Esparragosa Vázquez1, Carlos Toledano Illan1, Miguel Angel Idoate Gastearena1, Jaime Gállego Pérez-Larraya1 •
University of Navarra1
01 Jan 2020-Neuromuscular Disorders
TL;DR: A case of a man diagnosed with a non-microcytic lung carcinoma who started treatment with a combination of immune checkpoint inhibitors and subsequently developed binocular diplopia, fatigue, mild dyspnea and upper back pain resembling a myasthenia gravis presentation is reported.
Journal Article•10.1016/J.NMD.2020.08.357•
249th ENMC International Workshop: The role of brain dystrophin in muscular dystrophy: Implications for clinical care and translational research, Hoofddorp, The Netherlands, November 29th-December 1st 2019

[...]

Jos G.M. Hendriksen, Mathula Thangarajh1, Hermien E. Kan2, Francesco Muntoni3•
Virginia Commonwealth University1, Leiden University Medical Center2, Great Ormond Street Hospital3
15 Aug 2020-Neuromuscular Disorders
TL;DR: The role of brain dystrophin in muscular dystrophy: Implications for clinical care and translational research, 249th ENMC International Workshop, Hoofddorp, The Netherlands, November 29th–December 1st 2019.
Journal Article•10.1016/J.NMD.2020.10.008•
Long-term follow-up of patients with type 2 and non-ambulant type 3 spinal muscular atrophy (SMA) treated with olesoxime in the OLEOS trial

[...]

Francesco Muntoni1, Enrico Bertini2, Giacomo P. Comi3, Janbernd Kirschner4, Anna Lusakowska5, Eugenio Mercuri6, Mariacristina Scoto1, W. Ludo van der Pol7, Carole Vuillerot8, Alexander Burdeska9, M. El-Khairi9, Paulo Fontoura9, Jane Ives9, Ksenija Gorni9, Carol Reid9, Sabine Fuerst-Recktenwald9 •
UCL Institute of Child Health1, Boston Children's Hospital2, University of Milan3, University Hospital Bonn4, Medical University of Warsaw5, The Catholic University of America6, Utrecht University7, University of Lyon8, Hoffmann-La Roche9
05 Nov 2020-Neuromuscular Disorders
TL;DR: Overall, with no stabilization of functional measures observed over 130 weeks, OLEOS did not support significant benefit of olesoxime in patients with SMA, and this open-label extension study further characterizes the safety, tolerability and efficacy of oLESoxime over longer therapy durations.
Journal Article•10.1016/J.NMD.2020.03.001•
Facioscapulohumeral muscular dystrophy 1 patients participating in the UK FSHD registry can be subdivided into 4 patterns of self-reported symptoms.

[...]

Christopher R. S. Banerji1, Christopher R. S. Banerji2, Phillip Cammish3, Teresinha Evangelista3, Peter S. Zammit2, Volker Straub3, Chiara Marini-Bettolo3 •
Imperial College London1, King's College London2, Centre for Life3
12 Mar 2020-Neuromuscular Disorders
TL;DR: Investigating factors affecting rate of onset of 5 major FSHD symptoms found shorter D4Z4 repeat length associated with accelerated onset of each symptom, while pregnancy and carrying multiple children to term was associated with slower onset of all muscle symptoms.
Journal Article•10.1016/J.NMD.2020.10.002•
Electrophysiological study of neuromuscular junction in congenital myasthenic syndromes, congenital myopathies, and chronic progressive external ophthalmoplegia.

[...]

Vitor Marques Caldas1, Carlos Otto Heise1, João Aris Kouyoumdjian, A A Zambon1, André Macedo Serafim da Silva1, Eduardo de Paula Estephan1, Edmar Zanoteli1 •
University of São Paulo1
14 Oct 2020-Neuromuscular Disorders
TL;DR: Jitter and RNS assessment are valuable tools for diagnosing neuromuscular transmission abnormalities in CMS patients and strongly suggests CMS compared with CPEO and CM.
Journal Article•10.1016/J.NMD.2020.05.006•
Transportin 3 (TNPO3) and related proteins in limb girdle muscular dystrophy D2 muscle biopsies: A morphological study and pathogenetic hypothesis.

[...]

Roberta Costa1, Maria Teresa Rodia1, Sara Vianello2, Spartaco Santi, Giovanna Lattanzi, Corrado Angelini, Elena Pegoraro2, Giovanna Cenacchi1 •
University of Bologna1, University of Padua2
01 Aug 2020-Neuromuscular Disorders
TL;DR: The data suggest a possible interference in the morphology and function of myofibrillar network by mutated TNPO3, supported by the in silico identification of genes involved in muscle contraction that could help to explain the pathogenic mechanisms of LGMD D2.
Journal Article•10.1016/J.NMD.2020.08.360•
247th ENMC International Workshop: Muscle magnetic resonance imaging - Implementing muscle MRI as a diagnostic tool for rare genetic myopathy cohorts. Hoofddorp, The Netherlands, September 2019.

[...]

Jodi Warman-Chardon1, Jordi Díaz-Manera2, Giorgio Tasca, Volker Straub2•
Children's Hospital of Eastern Ontario1, Newcastle University2
26 Aug 2020-Neuromuscular Disorders
Journal Article•10.1016/J.NMD.2020.02.011•
The endocrine manifestations of spinal muscular atrophy, a real-life observational study.

[...]

Avivit Brener1, Avivit Brener2, Yael Lebenthal1, Anna Shtamler1, Sigal Levy, Ronnie Stein1, Aviva Fattal-Valevski1, Liora Sagi1 •
Tel Aviv Sourasky Medical Center1, Tel Aviv University2
24 Feb 2020-Neuromuscular Disorders
TL;DR: It is suggested that isolated precocious pubarche is associated with early-onset insulin resistance linked to severity of muscular atrophy, and this study aimed to provide a comprehensive description of the endocrine manifestations of SMA patients with variable degree of sarcopenia.
Journal Article•10.1016/J.NMD.2020.09.023•
Respiratory muscle training in late-onset Pompe disease: Results of a sham-controlled clinical trial

[...]

Harrison N. Jones1, Maragatha Kuchibhatla1, Kelly D. Crisp1, Lisa D. Hobson-Webb1, Laura E. Case1, Milisa T. Batten1, Jill Marcus1, Richard M. Kravitz1, Priya S. Kishnani1 •
Duke University1
28 Sep 2020-Neuromuscular Disorders
TL;DR: The magnitude of changes in MIP and MEP in the treatment group were consistent with the pilot findings but did not achieve statistical significance in comparison to controls, and therefore sham-RMT may not be an optimal control condition for RMT in LOPD.
Journal Article•10.1016/J.NMD.2020.02.010•
Exploring the efficacy of the expiratory muscle strength trainer to improve swallowing in inclusion body myositis: A pilot study.

[...]

Nika Mohannak1, Gemma Pattison2, Bronwyn Radich2, Kathryn Hird1, Erin Godecke3, Frank L. Mastaglia4, Merrilee Needham1 •
University of Notre Dame1, Royal Perth Hospital2, Edith Cowan University3, Murdoch University4
24 Feb 2020-Neuromuscular Disorders
TL;DR: Overall, IBM patients who used the EMST device demonstrated no improvement in swallowing function and there was also no change in measures of quality of life.
Journal Article•10.1016/J.NMD.2020.09.025•
Insulin-like growth factor-1 status is associated with insulin resistance in young patients with spinal muscular atrophy.

[...]

Avivit Brener1, Liora Sagi1, Anna Shtamler1, Sigal Levy, Aviva Fattal-Valevski1, Yael Lebenthal1 •
Tel Aviv Sourasky Medical Center1
20 Sep 2020-Neuromuscular Disorders
TL;DR: It is suggested that IGF-1 status is associated with insulin resistance in patients with early-onset sarcopenia and the Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) and IGF- 1.
Journal Article•10.1016/J.NMD.2020.02.007•
Beyond ambulation: Measuring physical activity in youth with Duchenne muscular dystrophy

[...]

Mary Killian1, Maciej S. Buchowski1, Thomas Donnelly1, W. Bryan Burnette1, Larry W. Markham2, James C. Slaughter1, Meng Xu1, Kimberly Crum1, Bruce M. Damon1, Jonathan H. Soslow1 •
Vanderbilt University Medical Center1, Riley Hospital for Children2
20 Feb 2020-Neuromuscular Disorders
TL;DR: A combination of QMT and accelerometry may provide a complementary assessment of skeletal muscle function in non-ambulatory boys with DMD and decline significantly over time.
Journal Article•10.1016/J.NMD.2020.06.001•
Mutation spectrum and health status in skeletal muscle channelopathies in Japan.

[...]

Ryogen Sasaki, Maki Nakaza1, Mitsuru Furuta, Haruo Fujino2, Tomoya Kubota1, Masanori P. Takahashi1 •
Osaka University1, Oita University2
01 Jul 2020-Neuromuscular Disorders
TL;DR: The etiology of skeletal muscle channelopathies in Japan was not identical to previous reports from Western countries, and provided crucial information for genetics as well as future therapeutic interventions.
Journal Article•10.1016/J.NMD.2020.05.005•
Mutations in the SIGMAR1 gene cause a distal hereditary motor neuropathy phenotype mimicking ALS: Report of two novel variants

[...]

Maxwell Ma1, Dong-Hui Chen1, Wendy H. Raskind1, Thomas D. Bird1•
University of Washington1
01 Jul 2020-Neuromuscular Disorders
TL;DR: The findings expand the number of known SIGMAR1 pathogenic variants associated with dHMN, which should be clinically distinguished from ALS, and identify two novel variants in the SIG MAR1 gene in the proband.
Journal Article•10.1016/J.NMD.2020.05.007•
Managing pregnancy and anaesthetics in patients with skeletal muscle channelopathies.

[...]

Dipa L. Raja Rayan1, Michael G. Hanna1•
UCL Institute of Neurology1
01 Jul 2020-Neuromuscular Disorders
TL;DR: The importance of counselling patients and clinicians for the possibility of worsening symptoms during pregnancy or anaesthesia and the careful management of neonates following delivery is highlighted.

Tools

SciSpace AgentBiomedical AgentSciSpace RecruitSciSpace for EnterpriseAgent GalleryChat with PDFLiterature ReviewAI WriterFind TopicsParaphraserCitation GeneratorExtract DataAI DetectorAI Humanizer

Learn

CompareGuidesLive Workshops

SciSpace

CareersSupportBrowse PapersPricingSciSpace Affiliate ProgramCancellation & Refund PolicyTermsPrivacyData Sources

Directories

PapersTopicsJournalsAuthorsConferencesInstitutionsPublishersCitation StylesWriting templates

Extension & Apps

SciSpace Chrome ExtensionSciSpace Mobile App

Contact

[email protected]
SciSpace

© 2026 | PubGenius Inc. | Suite # 217 691 S Milpitas Blvd Milpitas CA 95035, USA

soc2